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PURPOSE 
 
To retrospectively compare three dynamic contrast material–enhanced magnetic 
resonance (MR) imaging (dynamic MR imaging) analytic methods to determine the 
parameter or combination of parameters most strongly associated with changes in tumor 
microvasculature during treatment with bevacizumab alone and bevacizumab plus 
chemotherapy in patients with inflammatory or locally advanced breast cancer. 
 
 
MATERIALS AND METHODS 
 
This study was conducted in accordance with the institutional review board of the 
National Cancer Institute and was compliant with the Privacy Act of 1974. Informed 
consent was obtained from all patients. Patients with inflammatory or locally advanced 
breast cancer were treated with one cycle of bevacizumab alone (cycle 1) followed by 
six cycles of combination bevacizumab and chemotherapy (cycles 2–7). Serial dynamic 
MR images were obtained, and the kinetic parameters measured by using three dynamic 
analytic MR methods (heuristic, Brix, and general kinetic models) and two region-of-
interest strategies were compared by using two-sided statistical tests. A P value of .01 
was required for significance. 
 
 
RESULTS 
 
In 19 patients, with use of a whole-tumor region of interest, the authors observed a 
significant decrease in the median values of three parameters measured from baseline to 
cycle 1: forward transfer rate constant (K
trans
) (_34% relative change, P = .003), 
backflow compartmental rate constant extravascular and extracellular to plasma (Kep)    
(-15% relative change, P < .001), and integrated area under the gadolinium 
concentration curve (IAUGC) at 180 seconds (-23% relative change, P = .009). A trend 
toward differences in the heuristic slope of the washout curve between responders and 
nonresponders to therapy was observed after cycle 1 (bevacizumab alone, P = .02). The 
median relative change in slope of the wash-in curve from baseline to cycle 4 was 
significantly different between responders and nonresponders (P = .009). 
 
 
 
CONCLUSION  
 
The dynamic contrast-enhanced MR parameters K
trans
, Kep, and IAUGC at 180 seconds 
appear to have the strongest association with early physiologic response to 
bevacizumab. 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Dynamic contrast material–enhanced magnetic resonance (MR) imaging (dynamic MR 
imaging) can depict changes in the physiologic characteristics of tumors after a 
therapeutic intervention. Dynamic MR imaging has been used to monitor response to 
chemotherapy and for drug development; therefore, it may be clinically useful for 
determining prognoses (1–3). Bevacizumab (Avastin; Genentech, South San Francisco, 
Calif) is a recombinant humanized monoclonal antibody that binds specifically to and 
inhibits vascular endothelial growth factor (4,5). Because vascular endothelial growth 
factor is involved in the proliferation and differentiation of endothelial cells, it is an 
attractive intervention target that could be monitored with dynamic MR imaging. 
 
Conventional anatomic imaging depicts the physical size of tumors and is therefore 
considered a delayed indicator that might not enable reliable prediction of outcome. Use 
of dynamic MR imaging to characterize the tumor microvasculature is attractive 
because the technique is easy to implement, involves no radiation exposure (allowing 
repeated use), and generates semiquantitative information about vascular permeability 
and blood flow within tumors (6). Because dynamic MR imaging signal kinetics 
correspond to a tumor’s vascular parameters, quantification of these signals may be 
used to evaluate response to angiogenic inhibition (1,3). The pathophysiologic basis for 
these contrast material kinetics has been attributed to the hyperpermeability of 
angiogenic vessels (7). 
 
Compartment models such as the Brix model and the general kinetic model (GKM) 
(8,9), which are used to calculate the leakage of contrast material from the vascular 
space to the extravascular-extracellular space (leak rates) and the reflux of contrast 
material back to the vascular space (reflux rate), have been established. Previous 
dynamic MR imaging studies to examine the effects of anti–vascular endothelial growth 
factor treatment in athymic rats with human breast carcinoma xenografts have revealed 
decreases in fractional leak rates and reflux rates, compared with these rates in control 
animals, as early as 24 hours after treatment (10). Similar results were obtained with 
other preclinical models of ovarian cancer assessed with dynamic MR imaging (11). 
 
In a previous clinical trial (12), we observed substantial decreases in pharmacokinetic 
parameters during treatment in patients with previously untreated inflammatory or 
locally advanced breast cancer who underwent one cycle of bevacizumab as a 
monotherapy (cycle 1) followed by six cycles of combination bevacizumab, 
doxorubicin, and docetaxel therapy (cycles 2–7). Thus, the purpose of our study was to 
retrospectively compare three dynamic MR imaging analytic methods to determine the 
parameter or combination of parameters most strongly associated with changes in tumor 
microvasculature during treatment with bevacizumab alone and bevacizumab plus 
chemotherapy in patients with inflammatory or locally advanced breast cancer. 
 
 
MATERIALS AND METHODS 
 
Clinical Trial 
 
The data from a trial to evaluate the effects of bevacizumab, doxorubicin, and docetaxel 
in patients with previously untreated locally advanced or inflammatory breast cancer 
were analyzed (12). The trial was approved by the institutional review board of the 
National Cancer Institute and compliant with the Privacy Act of 1974. Eligible patients 
had stage III or IV inflammatory breast cancer or locally advanced breast cancer, which 
included stages IIB, IIIA, IIIB, and IIIC tumors (13). Signed informed consent was 
obtained from all patients before the initiation of treatment. The patients underwent a 
total of seven cycles of treatment: one cycle of therapy with bevacizumab (15 mg per 
kilogram of body weight) followed by six cycles of combination bevacizumab (15 
mg/kg), doxorubicin (50 mg/m2), and docetaxel (75 mg/m2) therapy, with a 3-week 
interval between cycles. All patients underwent dynamic MR imaging at baseline (ie, 
before therapy) and after therapy cycles 1, 4, and 7, 3 weeks after a cycle and no more 
than 2 days before the next cycle of chemotherapy or, in the case of the last cycle of 
chemotherapy, before definitive surgery. The last MR examination was performed 3 
weeks after the last cycle of chemotherapy and 4–6 weeks before definitive surgery to 
confirm the response to therapy. 
 
Measurable disease was quantified by using MR imaging according to the response 
criteria in solid tumors (RECIST) guidelines (14). The index lesion was the primary 
breast mass (if discrete), the enlarged axillary node, or both. One patient’s axillary 
adenopathy was followed up with computed tomography because of the limited field of 
view at MR imaging. Disease response was assessed by the same reader (C.K.C.) by 
using the sequence that revealed the abnormality most clearly. For assessment of the 
lymph nodes, the non–fat-suppressed dynamic sequence (see Dynamic Contrast-
enhanced MR Imaging Analysis) was used, whereas for assessment of the primary 
breast mass, measurements were obtained by using the contrast-enhanced fast spoiled 
gradientecho sequence. According to RECIST criteria, the longest axial dimension was 
recorded regardless of the orientation. Residual disease was assessed with reference to 
the original prechemotherapy images. (Also see Region-of-interest [ROI] selection in 
Dynamic Contrast-enhanced MR Imaging Analysis section.) Patients were divided into 
responders, who had a partial response to therapy, and nonresponders, who had stable or 
progressive disease after therapy (12). 
 
 
MR Imaging Techniques 
 
Imaging was performed with patients in the prone position by using a 1.5-T MR system 
(GE Healthcare, Waukesha, Wis) with a dedicated receive-only four-channel dual breast 
coil. Baseline transverse gradient-echo images were obtained with a 25–35-cm field of 
view set to encompass both breasts and the axilla. First, diagnostic T2-weighted images 
were obtained by using 5225/100 (repetition time msec/echo time msec), a section 
thickness of 5 mm, and a matrix of 128 x 256 pixels. Next, dynamic contrast-enhanced 
MR images were obtained with a three-dimensional spoiled gradient-echo sequence by 
using 8/4.2, a 25° flip angle, 4–5-mm-thick sections through the entire breast, an 
acquisition time of 30 seconds per data set, and a matrix of 128 x 256 pixels. After three 
baseline nonenhanced image acquisitions, an automatic injector (Medrad Spectris, 
Indianola, Pa) was used to intravenously infuse gadopentetate dimeglumine (Magnevist; 
Berlex Laboratories, Wayne, NJ) at 0.3 mL/sec, for a total of 0.1 mmol per kilogram of 
body weight (typically 15–20 mL), followed by a 50-mL normal saline flush. The 0.3 
mL/sec infusion rate was chosen to satisfy the Brix model. Continuous 30 second 
imaging data sets were obtained before, during, and after administration of the contrast 
medium for a total of 8 minutes to result in 20 repeated data sets. 
Dynamic Contrast-enhanced MR Imaging Analysis 
 
We compared three dynamic MR imaging analytic methods—the heuristic, Brix (8), 
and GKM (9) techniques and two approaches to defining the ROI (10). The analysis and 
ROI selection were performed by three authors (A.T., R.E., and B.J.W.) with 1–6 years 
experience in breast MR imaging. These three methods were chosen because they 
represent three approaches to modeling: With the heuristic approach, one makes no 
assumption about tissue compartmentalization, and the two methods based on tissue 
compartmentalization differ in terms of the assumptions made about the influence of 
measured (GKM technique) versus modeled (Brix technique) arterial input function on 
the kinetic parameter values. The results of these three methods were obtained by 
transferring the acquired images to a personal computer and processing them with two 
analysis programs that were developed in house and based on the interactive display 
language (IDL, Boulder, Colo): the Dynamic program for the Brix and heuristics 
methods and the Cinetool program (GE Healthcare) with a KinMode analysis module 
for the GKM method. The GKM computer model was provided by one of the authors 
(S.N.G.), who programmed the module into the Cinetool research software. 
 
The time–signal intensity data from each pixel on the image generated their own time–
signal intensity curves, which were then evaluated according to the dynamic MR 
imaging method used with the heuristic model or one of the pharmacokinetic models 
(Brix or GKM) (15). The parameters used for the heuristic model were direct 
measurements of the slopes of wash-in and washout curves and the integrated area 
under the gadolinium concentration curve (IAUGC) for the first 90 or 180 seconds after 
contrast material injection. The parameters derived for the Brix model were the 
amplitude of enhancement and the reverse transfer constant (8). The parameters derived 
for the GKM method were the forward transfer rate constant (K
trans
), the backflow 
compartmental rate constant extravascular and extracellular to plasma (Kep), and the 
extravascular-extracellular volume fraction, with the assumption of a mean parenchyma 
T1 value of 850 msec. These rate transfer constants were originally described by Kety 
(9) and were modified to incorporate two-compartment models (9,16,17). Arterial input 
functions were obtained by drawing an ROI around the aorta from a single central 
section. 
  
ROI selection. Because there is no standardized method of plotting or summarizing the 
data within an ROI, we used two techniques to determine which strategy yielded the 
most clinically meaningful results. First, we chose an ROI from a single section of the 
most enhanced area of the tumor—that is, we performed “hot spot” measurements (18). 
These ROIs were hand drawn on color maps created with the Brix model and then 
exported to the two other models. Second, we used a whole-tumor pixel-by-pixel 
averaging technique: The software automatically drew the ROI by using a region-
growing algorithm bounded by an assigned threshold value, encompassing 
approximately 90% of the tumor area. Whole-tumor regions included only numerical 
data from pixels with a goodness-of-fit index (R2 value) of at least 0.85, which 
effectively eliminated nonenhancing or poorly enhancing regions. We chose this 
technique on the basis of findings in a prior study that revealed no apparent advantage 
in subsampling tumor regions (19). 
 
Statistical analyses. In the current analysis, we used data from a single-arm, single-
stage study designed for enrollment of 20 examinable patients to achieve 95% power for 
the detection of a change in any of four parameters measured from baseline to the end of 
cycle 1, equal to 1 standard deviation of the change. The two-tailed Wilcoxon signed 
rank test (or t test when appropriate) with an a level of .05 was used to perform these 
analyses. 
 
The primary outcomes of these analyses were changes in each dynamic MR imaging 
parameter. Initial explorations indicated that actual differences between the baseline 
measurement and the cycle 1, 4, or 7 measurement were more dependent on the baseline 
value (B) than were the corresponding relative differences—for example, the relative 
difference of (C1 – B)/B for each parameter, where C1 is the cycle 1 value. Thus, these 
relative differences, converted into percentages, were used as the primary data for the 
analyses since the evaluation of absolute differences might have revealed greater bias as 
a function of the magnitude of the baseline values themselves. 
 
To test whether the percentage relative changes were associated with a statistically 
significant difference from zero, the Wilcoxon signed rank test was used. Comparisons 
between responders and nonresponders were performed purely as secondary exploratory 
evaluations with low power by using the exact Wilcoxon rank sum test. 
  
Because of the large number of parameters evaluated, the various degrees of 
independence from one parameter to another, and the exploratory nature of the study, to 
interpret results in the context of the multiple comparisons performed, only P values of 
less than .01 were considered to indicate statistical significance and P values of .01–.05 
were associated with trends. All reported P values were de-rived by using two-sided 
tests and are presented without adjustments for multiple comparisons. Analyses were 
performed by using 2001 SAS, version 8.2, software (SAS Institute, Cary, NC). 
 
 
 
RESULTS 
 
Patient Characteristics 
 
Twenty-one women aged 35–73 years (mean age, 51 years; median age, 50 years) were 
enrolled in the initial trial from October 1, 2001, to May 31, 2004. All enrolled patients 
underwent at least the first cycle of bevacizumab (cycle 1). One patient had 
noninflammatory locally advanced breast cancer. For the current analyses, the data of 
19 of the 21 patients were used. Dynamic contrast-enhanced MR imaging was per-
formed in 20 patients at baseline, in 18 patients after cycle 1, in 19 patients after cycle 4, 
and in 15 patients after cycle 7. Reasons for not completing all four MR examinations 
included the following: The patient size was too large, the tumor was too large and/or 
the procedure was too painful to tolerate, intravenous access could not be gained to 
perform the dynamic portion of the examination, or the patient was removed from the 
study. Longitudinal tumor dimensions ranged from 1.9 to 8.4 cm. To compare the 
change in dynamic MR imaging parameters according to clinical response (based on 
RECIST criteria), we assigned the 19 patients to a responder or nonresponder group. 
Thirteen patients were considered clinical responders (including one whose partial 
response was unconfirmed because surgery was performed before reassessment), and 
six were considered nonresponders (ie, patients with stable or progressive disease after 
therapy). One patient with a clinically partial response had a complete pathologic 
response. There were no clinically complete responders. 
 
Dynamic Contrast-enhanced MR Imaging Results 
 
Serial GKM K
trans
 parametric maps and gadolinium concentration–time curves (Fig 1) 
showed the distribution of high-vascular-permeability surface areas. A high degree of 
vascular permeability was observed on the initial maps (constructed at baseline and after 
cycle 1), but less vascular permeability was observed on the subsequent maps 
(constructed after cycles 4 and 7). The kinetics of gadolinium enhancement in the 
tumor, as shown in concentration-time curves, were presented for each map. The higher 
initial gadolinium concentration slope at baseline and after cycle 1 reflected increased 
compartmental wash-in of the contrast agent, and the time points after the wash-in peak 
reflected the compartmental outflow or washout. 
 
Longitudinal data (ie, baseline, cycle 1, cycle 4, and cycle 7 measurements) for eight 
parameters of the three analytic models—Brix amplitude of enhancement, Brix reverse 
transfer constant, slope wash-in, slope washout, IAUGC at 90 seconds, IAUGC at 180 
seconds, GKM K
trans
, and GKM Kep— were collected for all 19 patients who underwent 
MR imaging. Note that slope washout is the only parameter that can assume either a 
positive or a negative value, and it can change from positive to negative—and vice 
versa—after therapy. Also, because very small slope washout values were measured at 
base-line, modest absolute value changes could have led to substantial percentage 
changes in value relative to the baseline measurement. 
 
The initial results obtained by using ROIs based on hand-drawn areas around the most 
enhanced area of the tumor (ie, hot spot) indicated trends toward differences in the 
heuristic parameters slope wash-in (P = .04), slope washout (P = .02), and IAUGC at 
180 seconds (P = .049) between the responders and the nonresponders. Results also 
indicated trends toward differences in the GKM parameters K
trans
 and Kep (P > .01 for 
both). In addition, when the relative differences in measurements obtained from 
baseline to cycle 1 were examined according to response, only the values for the 
heuristic IAUGC at 90 seconds (P = .05) and the slope washout (P = .05) differed. For 
measurements obtained from baseline to cycle 4, there was a trend toward differences in 
the heuristic IAUGC at 180 seconds only (P = .03). There were no significant 
differences. 
 
At whole-tumor analysis, the results were considerably different (Table 1). Three 
parameters had a significant decrease as the relative change between baseline and cycle 
1: GKM K
trans
 (median relative change, -34%; P = .003), Kep (median relative change,     
-15%; P < .001), and IAUGC at 180 seconds (median relative change, -23%; P = .009). 
Between baseline and cycle 4 and between baseline and cycle 7, almost all parameters 
of the three models decreased (Fig 2, Table 1). For all parameters measured, the 
decrease in value was greater earlier in therapy (between cycles 1 and 4) than later in 
therapy (between cycles 4 and 7) (Table 2). We observed one trend toward a difference 
between the responders and the nonresponders when we compared the relative changes 
in all eight parameters from baseline to cycle 1 and from baseline to cycle 4: that for the 
median relative change in slope washout from baseline to cycle 1 (-104% for 
responders, 65% for nonresponders [P = .02]) (Table 3). Although the median relative 
change in slope wash-in from baseline to cycle 4 was significantly different between the 
responders (-60%) and the nonresponders (-31%) (P = .009), there was no significant 
difference in this parameter between the two groups from baseline to cycle 1 (Fig 3). 
 
 
 
DISCUSSION 
 
In this analysis, we found that after a single cycle of bevacizumab, all parameters of the 
three analytic methods decreased, suggesting that these parameters reflect vascular 
changes. However, only the GKM parameters K
trans 
and Kep and the heuristic model 
parameter IAUGC at 180 seconds were significantly different from the baseline values. 
A second, exploratory goal of the study was to determine whether dynamic contrast-
enhanced MR imaging might reveal an earlier change that could be associated with 
clinical outcome. After combination bevacizumab therapy and chemotherapy, the 
parameters of all methods decreased substantially. The possibility that changes in these 
parameters also result from prolonged and/or additional bevacizumab therapy cannot be 
ruled out; however, it is more likely that the combination of the angiogenic inhibitor and 
the chemotherapy had additive effects. The parameter values measured between cycles 
1 and 4 showed greater differences than did those measured between cycles 4 and 7, 
suggesting that the greatest effect on tumor microvascularity occurred early in the 
course of therapy. 
 
Although none of the assessed methods enabled successful prediction of the clinical 
response after cycle 1, we observed a significant difference in the heuristic slope wash-
in between the responders and the nonresponders at cycle 4 (P = .009). This finding 
suggests that choosing the appropriate time to obtain dynamic MR imaging data may 
improve the results. However, we speculate that this parameter was the only one that 
enabled differentiation between the two groups because of the change in tumor volume 
throughout the course of treatment and because semiquantitative calculations are less 
sensitive to noise from heterogeneous tissues. 
 
Our results indicate that methods in which arterial input functions are incorporated into 
the pharmacokinetic model or in which there is no attempt at physiologic correlation are 
the most reproducibly sensitive to angiogenic response to therapy. In that regard, our 
results from the heuristic model are consistent with previous results, which show that 
although the coefficient of variation for simple signal slopes (gradients) is higher than 
that for similar quantitative methods, IAUGC values may have a lower coefficient of 
variation than do other quantitative parameters (20). At comparisons of other heuristic 
parameters, such as maximal signal intensity change per time interval ratio and time to 
enhancement (time at which the signal intensity reaches 90% of its maximum), it has 
been shown that these parameters have a higher coefficient of variation (21). 
 
In our study, the significance of the IAUGC likely resulted from the fact that simple 
signal integration is more accommodating of “noisy” data and less sensitive to data 
heterogeneity. Although the IAUGC is sensitive to change, it is limited because it 
cannot enable differentiation of the shape of various enhancement patterns. For 
example, a simple continuous increase in signal intensity can yield the same IAUGC 
value as a sharp increase and rapid decrease that is characteristic of angiogenesis 
enhancement patterns. Confirmation and validation of these findings in larger studies 
are needed. 
Another important part of our analysis was the selection of the ROI on the MR image. 
We used the hot-spot and whole-tumor ROI selection methods. In a similar breast tumor 
study (18), a hot-spot method yielded results that were more useful than whole-tumor 
ROI method results for the differentiation of benign versus malignant disease (18). 
Although the results of another hot-spot technique indicated a larger difference between 
responders and nonresponders in a breast cancer neoadjuvant chemotherapy study (22), 
these results possibly were skewed because the whole-tumor data included the signal 
intensity of nonenhancing necrotic areas. In our evaluation, use of the hot-spot ROI 
method did not enable optimal detection of the small subtle changes that result from 
antiangiogenic therapy; however, when the whole tumor was evaluated, sensitivity 
improved. Moreover, determinations of the whole-tumor ROI were less subjective (23). 
Unlike the two previously described hot-spot methods, in which the analysis could have 
been biased owing to necrotic areas of the tumor, the ROI drawn by our automated 
ROI-drawing tool in the software supplied with the GKM algorithm included only 
numerical data from pixels with a goodness-of-fit index (R2) of at least 0.85, which 
effectively eliminated the nonenhancing or poorly enhancing regions. 
 
Our study had several limitations: First, because of the rarity of inflammatory breast 
cancer, the study included data from a small number of patients. Second, because 
invasive tumor cells in inflammatory breast cancer are distributed more heterogeneously 
throughout the affected breast tissue, discrete tumor measurement is more challenging. 
Despite this problem, we were able to identify important changes in dynamic MR 
imaging parameters after bevacizumab treatment. Our third limitation was due to the 
study design: Because the patients received only one cycle of bevacizumab 
monotherapy before undergoing combination chemotherapy, the information regarding 
the effects of bevacizumab alone was limited. To be conservative, we required a stricter 
interpretation of the level of significance associated with a given P value because of the 
large number of tested parameters. Other methods in subsequent analyses may involve 
parameters that are predictive if they are examined as single parameters. Finally, we 
were restricted to using a low contrast material infusion rate (0.3 mL/sec) to 
accommodate the requirements of the Brix model. It is unknown whether faster bolus 
infusion would have produced different results. 
 
In conclusion, our study results show that dynamic contrast-enhanced MR imaging can 
be used to reliably detect and characterize the effects of the angiogenesis inhibitor 
bevacizumab. We found that the MR-derived IAUGC and GKM parameters K
trans
 and 
Kep were the most strongly associated with changes in inflammatory breast cancer 
response after treatment with bevacizumab alone and combination bevaci-zumab 
therapy and chemotherapy. This may be because the GKM parameters are based on 
independent measurements of arterial input function and T1 correction—rather than MR 
signal intensity alone—for determination of gadolinium concentrations. Thus, the 
physiologic characteristics of individual patients are taken into account in these values. 
With continued improvements in dynamic contrast-enhanced MR imaging, such as 
faster acquisitions, improved postprocessing algorithms, and improved ROI analysis, 
we expect this method to contribute valuable prognostic information for angiogenic 
therapy. 
 
 
 
 
ADVANCES IN KNOWLEDGE 
 
MR-derived general kinetic model pharmacokinetic parameters and the integrated area 
under the gadolinium concentration curve are statistically significant methods of 
detecting changes in the response of inflammatory breast cancer to bevacizumab alone 
and bevacizumab combined with chemotherapy. 
 
The whole-tumor region-of-interest selection method with suitable thresholding yields 
better statistical correlations for parameter changes from baseline to cycle 1 (P = .003 
for forward transfer rate constant [K
trans
], P < .001 for backflow compartmental rate 
constant extravascular and extra-cellular to plasma [Kep], P = .009 for integrated area 
under the gadolinium concentration curve [IAUGC] at 180 seconds) than does the hot-
spot method (P > .01 for K trans and Kep, P = .049 for IAUGC at 180 seconds). 
 
 
IMPLICATIONS FOR PATIENT CARE 
 
Dynamic contrast-enhanced MR imaging may be a useful tool for assessment of 
vascularity changes in inflammatory breast cancer treated with antiangiogenic therapy. 
 
Region-of-interest selection is important for quantification of cancer response to 
therapy. 
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Figure 1. Change in serial transverse GKM K
trans
 parametric maps (calculated from 
transverse T1-weighted spoiled gradient-echo sequence [8/4.2, 25° flip angle, 4–5-mm 
section thickness]) (images at top) and gadolinium (Gd) concentration–time curves 
(graphs at bottom) for one patient from baseline to cycle 7 (C7). Tumor enhancement in 
the involved breast can be seen in color: Red and green indicate high enhancement, and 
blue indicates low enhancement. Gadolinium concentration–time curves show the rate 
of gadolinium-based contrast material perfusion throughout the tumor. Blue line 
represents arterial input function (AIfn). □ = ROI data, C1 = cycle 1, C4 = cycle 4, 
LMB = left mouse button, RMB = right mouse button. 
 
 
 
Figure 2. Graph illustrates absolute decreases in K
 trans
 from baseline to cycles 1 and 4. 
Two-sided P values were calculated with the Wilcoxon signed rank test (P=.003 for 
difference in K
trans 
between cycle 1 and baseline, P < .001 for difference between cycle 
4 and baseline). The horizontal line inside each box is the median quartile, the 
horizontal line below the box is the lower quartile, and the line above the box is the 
upper quartile. The vertical lines connect the quartiles. 
 
 
 
 
 
 
 
Figure 3. Graph illustrates differences in relative percentage change in slope wash-in 
from baseline between responders (patients with partial response to therapy) and 
nonresponders (patients with stable or progressive disease after therapy) (outliers not 
shown). Response was defined according to the RECIST guidelines. Two-sided P 
values were calculated by using Wilcoxon rank sum tests. The horizontal line inside 
each box is the median quartile, the horizontal line below the box is the lower quartile, 
and the line above the box is the upper quartile. The vertical lines connect the quartiles. 
 
 
 
Table 1. Relative Changes in Eight Parameters from Baseline to Cycle 1, from Baseline to Cycle 4, and 
from Baseline to Cycle 7 
Parameter 
Baseline to Cycle 1 Baseline to Cycle 4 Baseline to Cycle 7 
Median Percentage 
Change* 
P Value
†
 
Median Percentage 
Change* 
P Value
†
 
Median Percentage 
Change* 
P Value
†
 
Brix amplitude
‡
 -14 (-63 to 78) .35 -39 (-100 to 65) <.001 -39 (-100 to 43) .003 
Brix Kep -12 (-65 to 96) .15 -54 (-100 to 9) <.001 -60 (-100 to 11) <.001 
GKM K
trans
 -34 (-72 to 889) .003 -58 (-95 to 6) <.001 -76 (-98 to 2) <.001 
GKM Kep -15 (-54 to 17) <.001 -49 (-85 to 57) .002 -59 (-99 to -9) <.001 
Slope wash-in -24 (-83 to 118) .35 -55 (-84 to 24) <.001 -67 (-93 to 16) <.001 
Slope washout -64 (-1147 to 2133) .11 26 (-1700 to 1511) .89 -103 (-3935 to 271) .28 
IAUGC 90
§
 -27 (-86 to 33) .02 -60 (-100 to 0) <.001 -75 (-100 to -25) <.001 
IAUGC 180
§
 -23 (-72 to 38) .009 -53 (-93 to 0) <.001 -62 (-95 to -14) <.001 
*Values are percentage relative changes in the given parameter between the two time points indicated. Numbers in 
parentheses are ranges.  
† Two-sided P values calculated with the Wilcoxon signed rank test. 
‡ Brix model amplitude of enhancement. 
§ IAUGC at 90 or 180 seconds after contrast material injection. 
 
 
 
Table 2. Relative Changes in Eight Parameters from Cycle 1 to Cycle 4 and from 
Cycle 4 to Cycle 7 
 Cycle 1 to Cycle 4 Cycle 4 to Cycle 7 
Parameter 
Median Percentage 
Change* 
P Value† 
Median 
Percentage 
Change* 
P Value† 
Brix amplitude
‡
 -33 (-100 to 65) .003 2 (-100 to 120) .46 
Brix Kep -45 (-100 to 78) .002 -13 (-100 to 203) .86 
GKM K
trans
 -58 (-97 to 80) .01 -12 (-85 to 240) .76 
GKM Kep -47 (-84 to 134) .05 -14 (-96 to 296) .89 
Slope wash-in -47 (-81 to 245) .02 -10 (-83 to 180) .39 
Slope washout -28 (-1017 to 2806) .96 -38 (-519 to 228) .36 
IAUGC 90
§
 -50 (-100 to 200) .12 -35 (-100 to 50) .13 
IAUGC 180
§
 -44 (-94 to 71) .007 0 (-67 to 50) .52 
* Values are percentage relative changes between the two time points indicated. Numbers in 
parentheses are ranges. 
† Two-sided P values calculated with the Wilcoxon signed rank test. 
‡ Brix model amplitude of enhancement. 
§ IAUGC at 90 or 180 seconds after contrast material injection. 
 Table 3. Relative Changes in Parameters for Responders and Nonresponders 
Parameter and 
Patient Group* 
Baseline to Cycle 1 Baseline to Cycle 4 
No. of 
Patients 
Median    
Percentage  
Change
†
 
P 
Value
‡
 
No. of 
Patients 
Median 
Percentage 
Change
†
 
P 
Value
‡
 
Brix amplitude
§
   .57   .01 
Partial responders 13 -12 (-28 to 47)  13 -53 (-100 to -12)  
Nonresponders 5 -26 (-63 to 78)  6 -22 (-39 to 65)  
Brix Kep   .96   .34 
Partial responders 12 -19 (-65 to 96)  12 -66 (-100 to 9)  
Nonresponders 5 -10 (-44 to -4)  6 -40 (-84 to -24)  
GKM K
trans
   .77   .05 
Partial responders 13 -32 (-72 to 889)  13 -76 (-95 to 6)  
Nonresponders 5 -36 (-56 to -9)  6 -39 (-57 to -6)  
GKM Kep   .34   .09 
Partial responders 13 -14 (-33 to 17)  13 -61 (-85 to 57)  
Nonresponders 5 -16 (-54 to -2)  6 -24 (-59 to 50)  
Slope wash-in   .78   .009 
Partial responders 13 -24 (-83 to 47)  13 -60 (-84 to 6)  
Nonresponders 4 -11 (-64 to 118)  6 -31 (-55 to 24)  
Slope washout   .02   .06 
Partial responders 13 -104 (-1147 to 535)  13 -181 (-1700 to 400)  
Nonresponders 4 65 (-25 to 2133)  6 68 (26 to 1511)  
IAUGC 90
#
   .04   .24 
Partial responders 13 -14 (-67 to 33)  13 -67 (-100 to 0)  
Nonresponders 5 -60 (-86 to 0)  6 -54 (-71 to -25)  
IAUGC 180
#
   .08   .04 
Partial responders 13 -18 (-35 to 38)  13 -61 (-93 to 0)  
Nonresponders 5 -42 (-72 to 21)  6 -40 (-53 to -12)  
* Nonresponders are patients with stable or progressive disease after therapy. 
† Values are percentage relative changes between the two time points indicated. Numbers in 
parentheses are ranges. 
‡ Two-sided P values calculated with the Wilcoxon signed rank test. 
§ Brix model amplitude of enhancement. 
# IAUGC at 90 or 180 seconds after contrast material injection. 
 
